2025.04.23
*Announcement* Phase I/IIa Clinical Trial of Human (Allogeneic) Subcutaneous Adipose Tissue-Derived Mesenchymal Stem Cell Sheet (PAL-222) Transplantation in Neovascular Age-Related Macular Degeneration Refractory to Existing Treatments (Trial Title: PRESERVE Study)
We are pleased to report that the first transplantation operation has been completed with Yamaguchi University Hospital as the implementing medical institution under the support of Dr. Kimura of Division of Advanced Genome Editing Therapy.
In March 2025, Yamaguchi University and PharmaBio Co., Ltd. announced the completion of a clinical trial of human (allogeneic) subcutaneous adipose tissue-derived mesenchymal stem cell sheet (PAL-222) transplantation for neovascular age-related macular degeneration (AMD) resistant to existing treatments Progression Suppression and Retinal The first transplantation procedure has now been completed.
The study was initiated with the support of the Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, and the Research Institute for Cell Design Medical Science (Professor Kazuhiro Kimura), with Yamaguchi University Hospital as the implementing medical institution.
For details, please refer to the following link.
https://www.yamaguchi-u.ac.jp/weekly/40701/index.html